EMEA Schizophrenia Guidance Recommends Use Of Placebo & Comparator
Executive Summary
Short-term trials for new schizophrenia therapies should include both a placebo and an active comparator, the European Medicines Evaluation Agency recommended in its "Note for Guidance on the Clinical Investigation of Medicinal Products in the Treatment of Schizophrenia."